Thermal phase transitions in rotating QCD with dynamical quarks

Relativistic rotation causes a change of QCD critical temperatures. Various phenomenological and effective models predict a decrease of the critical temperatures in rotating QCD. Nevertheless, lattice simulations showed that the critical temperature in gluodynamics increases due to rotation. We extend the lattice study to the theory with dynamical fermions. We present the first lattice results for rotating QCD with $N_f=2$ dynamical clover-improved Wilson quarks. We also study separately the effect of rotation on gluonic and fermionic degrees of freedom. It is shown that separate rotations of gluons and fermions have opposite effects on the critical temperatures. In aggregate, the pseudo-critical temperatures in QCD increase with angular velocity. Dependence of the results on the pion mass is also discussed.Comment: 10 pages, 5 figures, Proceedings of the 39th International Symposium on Lattice Field Theory, 8th-13th August, 2022, Bonn, German

Current and future use of colchicine in patients with COVID-19

There exist some theoretical premises for the use of colchicine in patients with COVID-19, and clinical trials are underway. There is currently no published evidence confirming effectiveness and safety of colchicine in COVID-19 and allowing to recommend it for general practice. If prescribing colchicine, the one should perform clinical and hematological monitoring and avoid drug interactions

Improving the quality of electricity in the power supply systems of the mineral resource complex with hybrid filter-compensating devices

The urgency and necessity of choosing and justifying the structures of hybrid filter-compensating devices based on series and parallel active filters to improve the quality of electricity in the power supply systems of enterprises of the mineral resource complex is shown. Mathematical models of hybrid filter compensating devices based on parallel and series active filters have been developed. Based on these mathematical models, computer simulation models of the indicated hybrid structures have been developed. The results of simulation showed the effectiveness of the correction of power quality indicators in terms of reducing the level of higher harmonics of current and voltage, as well as voltage deviations. The degree of influence of filter-compensating devices on the power quality indicators, which determine the continuity and stability of the technological process at the enterprises of the mineral resource complex, have been revealed. It has been established that a hybrid filter-compensating device based on a parallel active filter can reduce the level of higher harmonics of current and voltage by more than 90 and 70 %, respectively, and based on a series active filter, it can reduce the level of higher harmonics of voltage by more than 80 %. Based on the simulation results, the possibility of compensating for the reactive power of a hybrid structure based on parallel active and passive filters has been revealed. The possibility of integrating hybrid filter-compensating devices into more complex multifunctional electrical systems for the automated improvement of the quality of electricity is substantiated, as well as the expediency and prospects of their use in combined power supply systems based on the parallel operation of centralized and autonomous sources of distributed generation

Current and future use of favipiravir in patients with COVID-19

There are experimental and clinical data regarding the activity of favipiravir against the SARS-CoV-2 virus. The is evidence of significant variability in pharmacokinetics and associated achievement of the required inhibitory concentration of the drug. The evidence base for the effectiveness of use in patients with mild to moderate COVID-19 is limited to open-label randomized clinical trials. The use of the drug, given the limited experience of using favipiravir, requires special attention to the safety of its prescription (pregnancy test, contraception compliance, control of uric acid, transaminases, ECG). At present, the prescription of the drug can be considered by the attending physicians if the expected benefits of its use prevail over the possible risks in accordance with the approved instructions for medical use and the temporary guidelines of the Ministry of Health of Russia

Possibilities for the use of tofacitinib in patients with COVID-19

No published trials measuring effectiveness of tofacitinib in COVID-19 have been identified. Some professional associations recommend discontinuing tofacitinib if SARS-CoV-2 infections is detected. Taken into account possible complications of the use of tofacitinib (infections, lymphopenia, venous thromboembolism), routine use of tofacitinib cannot be recommended unless within clinical trials under supervision of qualified healthcare professionals

Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab

No robust evidence proving clinical effectiveness of methylprednisolone in acute respiratory distress-syndrome in COVID-19, including combined use with tocilizumab, has been identified. Systemic glucocorticosteroids use may be considered acceptable in such patients in life-threatening situations, when interleukin-6 blockers (tocilizumab, sarilumab) are unavailable

Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19?

Hyaluronidase is currently not included into Russian or foreign guidelines on the treatment of acute respiratory distress-syndrome in patients with COVID-19, and such treatment is not supported by evidence of clinical effectiveness. Hyaluronidase can only be used for COVID-19 within clinical trials

Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice

Global experience with the clinical use of favipiravir is very limited. Its safety is for further study. Prevention of teratogenic effects (mandatory pregnancy test before starting therapy, compliance with effective contraception by both women and men), control of the level of uric acid, transaminases and ECG are of fundamental importance. Alertness is needed for new, insufficiently documented or previously unreported adverse events such as motor disturbances and falls. Patients should be fully informed about all the risks of therapy before starting it. Special attention is required to timely fill out the approved forms of notifications on the development of HP and report them in time according to the Order of the Federal Service for Surveillance in Healthcare of February 15, 2017 No. 1071 «On approval of the Procedure for the implementation of pharmacovigilance.

Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy

There are no data on the clinical efficacy of the preparation containing sodium aminodihydrophthalazindione in «cytokine storm», including in patients with COVID-19. Protocols of planned or ongoing clinical trials of a preparation containing sodium aminodihydrophthalazindione at COVID-19 have not been found. The use of sodium aminodihydrophthalazindione in the treatment of COVID-19 is possible only in clinical trials

What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?

Some guidelines describe combined use of hydroxychloroquine and lopinavir/ritonavir as one of the treatment alternatives for severe COVID-19, yet this treatment is not preferable. It requires careful consideration of possible interactions with other drugs, monitoring of cardiotoxicity (including QT-interval measurement), and hepatotoxicity (measurement of ASAT/ ALAT)